Uppsala May 29, 2023
LINK Medical, the Northern European clinical research organization (CRO), and AlzeCure® Pharma AB (publ) (FN STO: ALZCUR) announced earlier this week the positive data results from the Phase IIa clinical study with the non-opioid drug candidate ACD440, which is developed against peripheral neuropathic pain
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), is a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain.
- The phase II data show that ACD440 was able to demonstrate positive proof-of-mechanism (PoM) results in patients with chronic peripheral neuropathic pain, i.e. the drug candidate has an effect on the intended target mechanism.
- A significant analgesic effect was observed on pain induced by cold and heat. This temperature hypersensitivity is very common in the skin area, where the patients have their neuropathic pain, and is a major problem in everyday life for these individuals.
- These positive Phase II results are in line with previously reported Phase I results.
- ACD440 was well tolerated as a topical gel on the skin, which shows good suitability for continued clinical development, i.e. as a local treatment against neuropathic pain conditions.
“We are very pleased that in this pilot study, ACD440 was both well tolerated and able to demonstrate a good effect on the common factors that patients with peripheral neuropathic pain often experience as painful,” said Märta Segerdahl, project leader and CMO at AlzeCure Pharma. “Neuropathic pain is an area of great medical need, and we believe that ACD440 could significantly improve the quality of life for patients suffering from this type of pain.”
The Phase II clinical study, which was initiated in June 2022 and is being conducted in collaboration with LINK Medical Research, is a double-blind, placebo-controlled, randomized cross-over study to evaluate the efficacy and safety of AlzeCure’s lead drug candidate in pain, ACD440.
“The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments,” said AlzeCure Pharma’s CEO Martin Jönsson. “These new clinical data will help us increase interest in a license agreement with ACD440.”
“We are very happy about the positive results. This is a major milestone reached and a huge effort by many teams with excellent collaboration with AlzeCure. We look forward to the next steps and supporting AlzeCure in every way possible to drive success and reach the market.” said Sissel Lønning Andresen, CEO at LINK Medical.
ACD440 is a TRPV1 antagonist and first-in-class local treatment for patients with peripheral neuropathic pain. The discovery of TRPV1, which is the basis of the project, was awarded the Nobel Prize in Physiology or Medicine 2021. ACD440, which is applied as a gel, is the company’s leading drug candidate within the Painless platform and completed a positive phase Ib study in 2021.
About LINK Medical
LINK Medical is a Northern European drug and device development company with over 25 years of experience in partnering with pharmaceutical, biotech, and medtech companies.
We offer end-to-end solutions across all product development areas, from pre-to post-marketing. Our services include Clinical Development (CRO), Project Management, Biostatistics, Regulatory Affairs, Quality Assurance (QA), Chemistry Manufacturing and Controls (CMC) development, Pharmacovigilance, Market Access, and Real-World Evidence among other services.
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea, and Parkinson’s disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for the early treatment of Alzheimer’s disease and comprises two drug candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase and is continually working on business development to find suitable out licensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 email@example.com, is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.
About Neuropathic pain
Neuropathic pain affects approximately 7–8 percent of the total global adult population, approximately 600 million individuals. Some patients, with indications such as diabetes and HIV, are affected to a greater extent, where approximately 25 and 35 percent respectively of the patients experience neuropathic pain.
Peripheral neuropathic pain is the result of various types of damage to the nerve fibers, such as toxic, traumatic or nerve compression injuries as well a metabolic and infectious diseases. Common symptoms are painful tingling that can be described as “pins and needles”, or choking or burning pain, as well as the feeling of getting an electric shock. Patients may also experience allodynia (pain caused by a stimulus that usually does not cause pain) or hyperalgesia (increased pain from a stimulus that normally provokes pain).
The market for neuropathic pain is characterized by a major medical need in all indications and in all major markets, where about 70-80 percent of patients do not get effective pain relief with existing treatment. Due to the risk of abuse, overdose, and secondary damage, people now try to avoid opiates as first-line treatment for pain conditions. Despite this treatment problem, these preparations are still used frequently, and therefore the need for new treatments that are not opiates is very great.
The patient population will grow, among other things, due to an aging population and an increased number of long-term cancer survivors, and an increasing prevalence of type-2 diabetes.
The global market for neuropathic pain was valued at $11 billion in 2020 and is expected to grow to $25 billion by 2027.
For more information, please contact
Sissel Lønning Andresen, CEO
Tel: +47 41641451
Claudia Wennberg, Sr. Marketing and Brand Manager
Martin Jönsson, CEO
Tel: +46 707 86 94 43